These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3538563)

  • 1. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine.
    Kahan BD; Kramer WG; Wideman CA; Frazier OH; Lorber MI; Williams C; Flechner SM; Cooley DA; Van Buren CT
    Transplant Proc; 1986 Dec; 18(6 Suppl 5):115-9. PubMed ID: 3538563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR; Vanrenterghem Y
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.
    Rowshani AT; Scholten EM; Bemelman F; Eikmans M; Idu M; Roos-van Groningen MC; Surachno JS; Mallat MJ; Paul LC; de Fijter JW; Bajema IM; ten Berge I; Florquin S
    J Am Soc Nephrol; 2006 Jan; 17(1):305-12. PubMed ID: 16306168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.
    Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Choc M; Wong R
    Transplantation; 1995 Feb; 59(4):505-11. PubMed ID: 7878754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of performance factors affecting two formulations of cyclosporine in pediatric renal transplant patients.
    Acott PD; Crocker JF; Renton KW
    Transplant Proc; 2006 Nov; 38(9):2835-41. PubMed ID: 17112843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between area under the concentration versus time curve of cyclosporin A, creatinine clearance, hematocrit value, and other clinical factors in Japanese renal transplant patients.
    Shibata N; Hoshino N; Minouchi T; Yamaji A; Park K; Tomoyoshi T; Abe H; Kodama M
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):202-9. PubMed ID: 9587046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single daily dose administration of cyclosporine in renal transplant recipients.
    Halim MA; Said T; Al-Otaibi T; Eleawa S; Al-Maged H; Gawish AE; Nair P; Al-Muzairai I; Nampoory MR; Al-Mousawi M
    Transplant Proc; 2007 May; 39(4):1225-7. PubMed ID: 17524939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation.
    Savoldi S; Kahan BD
    Transplant Proc; 1986 Dec; 18(6 Suppl 5):120-8. PubMed ID: 3538564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do cyclosporin profiles provide useful information in the management of renal transplant recipients?
    Bowles MJ; Waters JB; Lechler RI; Williams G
    Nephrol Dial Transplant; 1996 Aug; 11(8):1597-602. PubMed ID: 8856218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients.
    Kuo PC; Luikart H; Busse-Henry S; Hunt SA; Valantine HA; Stinson EB; Oyer PE; Scandling JD; Alfrey EJ; Dafoe DC
    Clin Transplant; 1995 Apr; 9(2):92-7. PubMed ID: 7599409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.